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Title: Emerging genetic alterations linked to male infertility: X-chromosome Copy 20 
Number Variation and Spermatogenesis regulatory genes’ expression 21 
Abstract 22 
The etiopathogenesis of primary testicular failure remains undefined in 50% of cases. 23 
Most of these idiopathic cases probably result from genetic mutations/anomalies. Novel 24 
causes, like Copy Number Variation and gene expression profile, are being explored 25 
thanks to recent advances in the field of genetics. Our aim was to study Copy Number 26 
Variation (CNV) 67, a patient-specific CNV related to spermatogenic anomaly and 27 
evaluate the expression of regulatory genes AKAP4, responsible for sperm fibrous sheet 28 
assembly, and STAG3, essential for sister chromatid cohesion during meiosis. One 29 
hundred infertile men were tested for CNV67 with quantitative PCR (qPCR). Quantitative 30 
real-time PCR was performed to evaluate gene expression patterns of the two mentioned 31 
genes in testicular biopsies from 22 idiopathic infertile patients. 32 
CNV67 deletion was found in 2% of patients, with the same semen phenotype described 33 
in previous studies. Expression levels of AKAP4 and STAG3 were downregulated in 34 
infertile patients when compared to control group (p<0.05).  35 
Resulting data reinforce the role of CNV67 in male infertility etiology. Its frequency is 36 
significantly higher in oligo/azoospermic men and evidence indicates consistency of 37 
phenotype. Downregulation of AKAP4 and STAG3 cellular transcript levels was observed 38 
in the testicular biopsies, suggesting that the gene expression is altered, contributing to 39 
unsuccessful sperm production.  40 
As one continues to better understand about the genetics of male infertility, there will be 41 
undoubtedly a shift towards better diagnosis and treatment for those patients presenting 42 
idiopathic infertility. 43 
  
Keywords: Male Infertility; Spermatogenesis; DNA copy number variations; Gene 44 
expression.  45 
BACKGROUND 46 
An estimated 15% of couples are infertile, not achieving a clinical pregnancy after 1 year 47 
of unprotected intercourse, with a great impact on the individual, couple and society [1, 48 
2]. Male reproductive dysfunction is the sole or contributory cause of infertility in half of 49 
the couples [3, 4], with abnormalities of sperm number (azoospermia, oligozoospermia), 50 
motility (asthenozoospermia) and morphology (terathozoospermia) being frequently 51 
diagnosed [5, 6]. 52 
 53 
Male infertility can be clinically divided in three main categories: acquired, congenital 54 
and idiopathic, when no cause is identified [6, 7]. The idiopathic group still represents 55 
50% of the cases of primary spermatogenic failure in humans [2, 8] and presently, due to 56 
the lack of pathophysiological understanding, no specific treatment is offered [9]. Most 57 
of the underlying causes are thought to be genetic [6, 10, 11], mainly due to 58 
spermatogenesis defects [3, 12], correlated, or not, with environmental factors. 59 
Spermatogenesis is a highly complex process controlled by several regulatory genes 60 
which assure the correct maturation steps, from spermatogonia to sperm [3]. These men 61 
are otherwise usually healthy, suggesting that any genes involved must either be only 62 
expressed or be functionally required for spermatogenesis [3].   63 
 64 
During the last years, novel tests and diagnostic tools have been employed to identify rare 65 
genetic mutations and polymorphism with putative direct or indirect effects on 66 
spermatogenesis. The declining cost and increased power of whole-genome sequencing 67 
studies, including evaluation of the increasingly important intergenic regions of the 68 
  
genome, is leading to nascent paths of research and likely indicate that, in the future, such 69 
studies will be used on daily-basis [13]. Likewise, genetic testing of Copy Number 70 
Variation and spermatogenesis’s regulatory genes expression may reveal the etiology of 71 
idiopathic patients and, consequently, increase the likelihood of successful paternity and 72 
reduce potential risks to the progeny [13, 14]. 73 
 74 
Copy Number Variation (CNV) has raised a considerable interest among scientific and 75 
medical communities. CNV is conventionally defined as a DNA segment, 1 kb or longer, 76 
that is present in a variable number of copies in the genome, between individuals [15]. 77 
Since the first comprehensive CNV map of the human genome, in 2006, several diseases 78 
have been linked to CNVs, mainly due to disruption of functional elements (either genes 79 
or regulatory elements). In fact, it is well established that Y chromosome CNVs in the 80 
AZF region are linked to spermatogenic impairment and are routinely analysed for 81 
genetic male infertility diagnosis [9, 16]. These unbalanced quantitative variants can be 82 
classified into gains (increased number of DNA copies compared to reference genome) 83 
and losses (reduction or deletion compared to reference genome) [15]. 84 
 85 
Recently, high-resolution X-chromosome specific array-comparative genomic 86 
hybridization (aCGH) identified CNVs which could be related with male infertility [17]. 87 
X chromosome genes are particularly tempting because men are hemizygous for the X-88 
genes. Since compensation by a normal allele is impossible, it is more likely that a 89 
mutation may affect the fertility of an individual [6, 10]. From the reported CNVs, 90 
CNV67 was one of the most promising candidates, resembling AZF deletions of the Y 91 
chromosome [16, 17]. 92 
 93 
  
CNV67 deletion was exclusively found in infertile patients at a frequency of 1.1% 94 
(p<0.01), ranging patient’s phenotypes from azoospermia due to Sertoli-Cell-Only 95 
Syndrome (SCOS) to oligozoospermia. It is localized in Xq28 and is likely to be 96 
maternally inherited [16]. It has been suggested that CNV67 deletion linked to 97 
spermatogenic failure may be related to highly duplicated genes of X-Cancer Testis 98 
Antigen (CTA) family, the most represented X-linked testis specific family. In fact, X-99 
CTA genes comprise 10% of all X-linked genes and are expressed specifically in testis. 100 
[18]. In particular, CNV67 deletion may remove the melanoma antigen family A, 9B 101 
(MAGEA9B), expression levels in spermatocytes and in some tumour cell lines. It may 102 
also affect chromosome X open reading frame (CXorf40A), situated at < 1Mb from the 103 
deletion and regulation elements of Heat Shock Transcription Factor Family, X-Linked 104 
1/2 (HSFX1/2) [16, 17]. 105 
Gene expression profile can be used as a basis for identification of candidate genes that 106 
contribute to male infertility [19-21]. To date, genetic studies in mice have identified more 107 
than 200 genes that are specifically or preferentially involved in the complex regulation 108 
of fertility and some are specifically expressed in the germ line [6, 10, 11, 19]. AKAP4 109 
and STAG3 are strong candidate genes for male infertility [7, 22]. 110 
The A-kinase anchor protein 4 (AKAP4), an X-linked member of the AKAP gene family, 111 
encodes the most abundant protein of the spermatozoon’s fibrous sheet, a cytoskeletal 112 
structure surrounding the region of the principal piece of sperm flagellum [23]. AKAP4 113 
anchors cAMP-dependent protein kinase A (PKA) to the sperm fibrous sheet, which is 114 
essential for sperm capacitation, playing a central role in the regulation of normal sperm 115 
motility [11, 24, 25]. In fact, studies have shown that in AKAP4-deficient mice, though 116 
sperm count was not reduced, they were immotile, resulting in male infertility [6, 11]. 117 
Furthermore, another study verified no detection of AKAP4 immunolabeling in man with 118 
  
0% sperm mobility [19]. Therefore, AKAP4 is likely required for the structural and 119 
functional integrity of the fibrous sheath [25].  120 
Stromalin 3 (STAG3) is a component of all meiosis-specific cohesion complexes, a large 121 
ring-shaped proteinaceous structure which tethers sister chromatids, providing cohesion 122 
to the structure [22, 26]. Its deletion has been related to a Premature Ovary Failure (POF). 123 
Interestingly, STAG3-deficient male mice display a severe defect in synapses and 124 
premature loss of centromeric cohesion during the early stages of prophase I, which 125 
causes an arrest during the zygotene-like stage, leading to infertility [22, 27].  126 
 127 
The aim of this study is to explore these emerging genetic alterations by quantifying the 128 
copy number variation of CNV67 in a group of infertile men and consolidate the 129 
pathophysiology which links CNV67 to male infertility. In addition, the expression of 130 
spermatogenesis regulatory genes AKAP4 and STAG3 will be evaluated in infertile men 131 
testicular biopsies and correlated with the (in)fertility status. 132 
 133 
MATERIALS AND METHODS 134 
This study includes two distinct analyses – CNV67 screening and expression profile of 135 
AKAP4 and STAG3. Each analysis design will be explained separately.  136 
CNV67 screening analysis  137 
Patient samples 138 
 Peripheral blood samples were collected from 100 Portuguese idiopathic infertile men, 139 
with different grades of spermatogenic impairment - 44 azoospermic (AZO), 47 severe 140 
oligozoospermic (SOZ), 4 oligozoospermic (OZ) and 5 normozoospermic (N) men (Table 141 
1). Infertile patients were selected on the basis of a comprehensive andrological 142 
  
examination including medical history, semen analysis, scrotal ultrasound, and hormonal 143 
and genetic analysis. Patients with abnormal karyotype or Y chromosome microdeletion 144 
were excluded. Normal controls were fertile normozoospermic volunteers.  145 
Genomic DNA (gDNA) extraction 146 
Peripheral blood (3–5 mL) was collected through vein puncture from all participants. 147 
High molecular weight DNA was isolated using a salting out method. 148 
Quantitative PCR (qPCR) 149 
The number of copies of CNV67 on each sample was determined by Quantitative PCR 150 
(qPCR). TaqMan® probes were designed by the manufacturer (Applied Biosystems, 151 
Foster City, USA) and were chosen to target specific regions. Hs03323870_cn was 152 
selected for the target CNV67 (labeled with FAM) and Hs03323870 was selected for 153 
RNase P (labeled with VIC) and used as the reference gene. Reactions were performed in 154 
triplicate in a final volume of 20 µL according to the manufacturer’s instructions. Briefly, 155 
the components of the reaction mix were: 4 µL genomic DNA, 10 µL 2X TaqMan® 156 
Genotyping Master Mix, 1 µL 20X TaqMan® Copy Number Assay, 1 µL 20X TaqMan® 157 
Copy Number Reference Assay (RNase P) and 4 µL nuclease-free water. qPCR was 158 
carried out on a StepOnePlus™ Real-Time PCR System (Applied Biosystems). The 159 
thermal cycling conditions were as follows: Initial enzyme activation for 10 minutes at 160 
95°C, 40 cycles were performed, each one consisting of 15 seconds at 95°C and 60 161 
seconds at 60°C. 162 
 163 
Data Analysis 164 
Applied Biosystems CopyCallerTM Software v2.0 was used to determine the copy number 165 
status of each target region, and calculations were performed according to the maximum-166 
  
likelihood algorithm of the software. Raw copy value (RCV) represents a non-integer 167 
number of copy calculated, whereas predicted copy number (PCN) is defined as an integer 168 
number of copy determined by the algorithm (0, 1, 2, or 3+). As CNV67 is located on X-169 
chromosome, normal females will display PCN of 2 and normal males PCN equal to 1. 170 
In the case of male alteration, Copy Number (CN) gain is defined as PCN higher than 1, 171 
and PCN of 0 is regarded as CN loss. 172 
AKAP4 and STAG3 expression 173 
Patient samples 174 
Testicular samples were collected from 22 idiopathic infertile men with AZS (used as 175 
cases). Seven men with secondary infertility were used as controls. Testicular biopsies 176 
were obtained to confirm the clinical diagnosis (diagnostic biopsy) or for sperm retrieval 177 
(Testicular Sperm Extraction: TESE) to intracytoplasmic sperm injection (treatment 178 
biopsy). Patients with abnormal karyotype or Y chromosome microdeletion were 179 
excluded. Clinical information of each sample is shown in Table 2. 180 
Each sample was divided into three aliquots: one was reserved for histological analysis, 181 
the second (100-200mg) was processed for sperm extraction and the third (10mg) was 182 
immediately transferred to a 1.5mL tube with mRNA later® solution (Ambion®, Foster 183 
City, USA) and stored at -80ºC for further gene expression studies. 184 
 185 
RNA isolation and reverse transcription (RT) reaction 186 
After thawing the frozen pellets, cells were lysed on ice with 1000μL of TriPure Isolation 187 
Reagent (Roche Diagnostics, Indianapolis, USA) and passed several times through a 188 
syringe and needle. The total mRNA was then extracted according to the associated 189 
protocol. At the end, RNA pellet was resuspended in 50μL of diethylpyrocarbonate 190 
  
(DEPC)-treated RNase-free water (Promega, Wisconsin, USA) and incubated for 1h on 191 
ice. RNA was then quantified in a Biotech Photometer UV 1101 (WPA, Cambridge, UK). 192 
1µg of mRNA in a total volume of 10μL was reverse transcribed to complementary DNA 193 
(cDNA) using qScriptTM cDNA SuperMix (Quanta, BiosciencesTM, Gaithersburg, USA), 194 
with random hexamers as the priming method and according to the manufacturer’s 195 
instructions. 196 
Gene expression analysis by quantitative real-time PCR (qRT-PCR) 197 
TaqMan® Gene Expression Assays were used for both targeted experimental genes 198 
(AKAP4 - Hs00275849_m1 and STAG3 - Hs00429370_m1) All TaqMan® probes were 199 
labeled with FAM dye and were purchased from Applied Biosystems. RNA 18S 200 
Ribosomal (18S) was used as the housekeeping gene and TaqMan® Gene Expression 201 
Assay was also utilized. 202 
RNA expression levels were analysed by qRT-PCR on a StepOnePlus™ Real- Time PCR 203 
System (Applied Biosystems). qRT-PCR was performed in a volume of 10μL, using 2μL 204 
of cDNA, 2.5µL of Nuclease Free-water, 5µL of 2xKAPA probe MasterMix (Kappa 205 
Biosystems, Boston, Massachusetts, USA) and 0,5µL of 20X TaqMan® Gene Expression 206 
Assay for each gene, using a Fast Protocol according to manufacturer instructions. 207 
Briefly, after initial enzyme activation for 2 minutes at 50°C and 20 seconds at 95°C, 40 208 
cycles were performed, each one consisting of 3 seconds at 95°C and 20 seconds at 60°C. 209 
Standard curves were performed with five points, in duplicates. Each PCR for relative 210 
quantification was run in triplicate (technical replicates) and all genes were run together 211 
with a negative control. 212 
Data analysis and statistics 213 
Data was analyzed using REST 2009 (Relative Expression Software Tool), which is a 214 
standalone software tool that estimates up and downregulation for gene expression studies 215 
  
(http://www.qiagen.com/rest). The purpose of this software is to determine whether there 216 
are significant differences between samples and controls, while taking in account issues 217 
of reaction efficiency and reference gene normalization. The obtained hypothesis test 218 
P(H1) represents the probability of the alternate hypothesis that the difference between 219 
the sample and control groups is due only to chance. Real time PCR-negativity was 220 
defined by the absence of amplified product after 40 cycles and because REST software 221 
uses Ct values and reaction efficiency for calculations instead of relative expressions 222 
values, we proposed that the value of the last cycle of amplification (Ct = 40 cycles) 223 
should correspond to the value of absence of relative expression. Wilcoxon Signed Rank 224 
Test was used for the statistical analysis (StatView for Windows) with the significance 225 
level set at p < 0.05. 226 
 227 
RESULTS AND DISCUSSION 228 
CNV67 screening analysis 229 
In order to screen CNV67 deletion, 100 samples were studied from infertile men with 230 
different sperm phenotypes and concentration, as previously described, by RT-PCR 231 
(Table 1). Two individuals – Y3790 and Y3803 – were found to have deletion (0 copies) 232 
of CNV67 (2%). Y3790 was azoospermic, diagnosed with SCOS after biopsy and Y3803 233 
presented a severe oligozoospermia (2 x106 sperm/mL) (Fig. 1). Our data supports the 234 
sperm phenotypes related to CNV67 deletion (azoospermia in a clinical context of SCOS 235 
or oligozoospermia). Moreover, the findings indicate a significantly higher frequency in 236 
our Portuguese population, even though our sample was quite small when compared to 237 
previous studies [16, 17]. Whether the observed deletion is directly responsible for the 238 
altered sperm phenotype (either affecting gene expression or regulatory elements) or is 239 
related to increased genomic instability remains uncertain [17]. 240 
  
AKAP4 and STAG3 expression 241 
Quantification of testicular mRNA levels of genes expression was carried out by qRT-242 
PCR in individuals showing spermatogenic failure. Two spermatogenesis related genes - 243 
AKAP4 and STAG3 – were analyzed in 20 and 22 testicular biopsies samples, 244 
respectively. Clinical and pathologic information on the cases and controls are presented 245 
in Table 2. 246 
Analysis of the qRT-PCR results was completed by using REST 2009 software. The 247 
findings are summarized in Table 3. For reference gene normalization, 18S housekeeping 248 
gene was used. Sample expression ratios were calculated with REST software using the 249 
following formula:  250 
Relative Expression = Concentration of Gene of interest ÷ Geometric mean 251 
(concentration of reference gene 1, concentration of reference gene 2,…)  252 
With the use of this software, the up or downregulation for each gene expression was 253 
estimated comparing cases with controls. Results indicated that the AKAP4 and STAG3 254 
were downregulated with statistical significance (p<0.05) in the case group compared to 255 
the control group (Table 3; Fig. 2).  256 
Interestingly, 6 cases (w147, w149, w154, w176, w186, w195) did not express AKAP4 257 
and w220 patient did not express STAG3 (see Table 2). It has been demonstrated that the 258 
reduction of gene expression in spermatogenic failure patients could not be exclusively 259 
attributed to a decreased number of germ cells, but the contribution of the reduced cellular 260 
expression should be also taken in account [19].  261 
AKAP4 encodes a protein involved in fibrous sheet assembly and its regulation [28], and 262 
is exclusively expressed in germ cells, during the post-meiotic phase of spermatogenesis 263 
[25, 29]. The findings of this study on AKAP4 expression exhibit a statistically significant 264 
difference with downregulation in the case group. Interestingly, no expression was 265 
  
detected in several SCOS patients. However, the 2 oligo-asthenozoospermic [23] patients 266 
used as controls expressed AKAP4, contradicting the data published in a previous study. 267 
Similarly, downregulation of STAG3 was found in the case group. The STAG3 encodes a 268 
predominant STAG protein component of cohesin complexes in primary spermatocytes, 269 
participating in the telomere attachment to the nuclear periphery, telomere maintenance, 270 
chromosome pairing, chromosome synapses and maintenance of sister chromatid 271 
cohesion [27]. This protein is exclusively expressed in meiosis.  272 
 273 
Gene expression profiles can be used as a basis for identification of candidate genes that 274 
contribute to spermatogenic impairment. One must emphasize that an inherent problem 275 
in investigating testicular expression changes is the cellular complexity of the organ [21]. 276 
Here we analyzed the transcriptional changes in a complete organ, with distinct germ cell 277 
types. One advantage is that we revealed complex transcriptional changes related to the 278 
whole testis during germ cell differentiation. The same point has the inherent 279 
disadvantage, compared with isolated cell fractions, as we cannot directly identify the 280 
locus of expression change. Furthermore, whether the observed differential expression 281 
profiles represent the cause or consequence of spermatogenic impairment remains to be 282 
elucidated. This data should be useful in delineating the patterns of gene expression 283 
involved in male germline, which may contribute to understanding male infertility. 284 
CONCLUSION 285 
Classic male infertility tests, like karyotyping, Y chromosome microdeletions and FISH 286 
analysis at somatic and germ cell levels, are no longer sufficient to investigate the 287 
potential contribution of genome disorders on male infertility. A wide range of molecular 288 
  
methods are required for better understanding of male infertility causes and, therefore, 289 
increase the potential offer for a better treatment for infertile patients [30]. 290 
Novel genetic alterations have been identified which may be of potential clinical 291 
relevance in the etiology of male infertility in the medium term, like Copy Number 292 
Variation (CNV). Of all CNVs related to male infertility, X-CNV67 was one of the most 293 
interesting ones [16], with a consistent phenotype and significant frequency. It is likely 294 
that rare single nucleotide polymorphisms (SNPs) and CNVs, although they are rare on 295 
an individual basis, collectively they can contribute to explain a significant number of 296 
cases of male infertility that are currently classified as idiopathic. [13].  297 
 298 
The present study also explores gene expression profile as an emerging genetic alteration 299 
with implications in male infertility. Therefore we assessed the expression profile of 300 
regulatory genes AKAP4 and STAG3 on infertile men testicular biopsies. Our data reports 301 
altered expression of germ-line regulatory genes, providing an initial glimpse into the 302 
complex regulatory network controlling germ line development. Further analyses in 303 
larger series are required to better understand the biological implications of these 304 
differences.  305 
 306 
Although the importance of diagnosing genetic factors is fully recognized, the diagnostic 307 
workup of infertility in men is still limited to a few genetic tests [17]. Genetic testing 308 
allows clarifying an obscure infertility diagnosis and help to prevent miscarriage and 309 
iatrogenic transmission of genetic defects to the offspring through Assisted Reproduction 310 
Techniques (ART) [3, 4]. Therefore, we believe that efforts should be made in order to 311 
identify potential genetic causes of infertility and, in this way, aid couples to make 312 
informed decisions, optimize genetic testing and provide therapeutic targets [2, 31]. 313 
  
 314 
In conclusion, our findings merit further investigation in order to elucidate the potential 315 
of CNV67 in routine fertility workup and the role of AKAP4 and STAG3 in male 316 
infertility.  317 
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FIGURE SECTION 425 
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 434 
Fig. 1 – Copy Number Variation 67 deletion of infertile man Y3790 and Y3803. Whiskers 435 
refer to maximum and minimum of copies calculated. As CNV67 is located on X-436 
chromosome, normal females will display Predicted Number of Copies (PCN) of 2 and 437 
normal males PCN equal to 1. In the case of male alteration, Copy Number (CN) gain is 438 
defined as PCN higher than 1, and PCN of 0 is regarded as CN loss. YF154 – Fertile man 439 
control. 440 
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Fig. 2 – Expresion levels of AKAP4 and STAG3 in testicular samples. cDNA expression 460 
was normalized using a housekeeping gene (18S). Boxes represents the interquartile 461 
range, or the middle 50% of observations. The dotted line represents the median gene 462 
expression. Whiskers represent the minimum and maximum observations. Significance 463 
differences between groups are represented as: * p<0.05. The data was analysed by Mann-464 
Whitney-Wilcoxon test.  465 
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Table 1 – Clinical description of the study population 
Patient’s semen phenotype (n=100) 
Azoospermic 
Severe oligozoospermic (5x106/mL) 
Oligozoospermic (5-15x106/mL) 
Normal 
 44 
47 
4 
5 
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Table 2 - Clinical description of the study population 
Patients 
(n=29) 
 
ID 
 
Diagnosis 
 
TESE 
 
Clinical history 
 
Cases (n=22) w1 AZS SCOS Normal 
 w77 AZS MA Normal 
 w113 AZS MA Hypospadias, Orchitis (28yo, 29yo) 
 w119 AZS MA Left testicular torsion 
 w131 AZS HP Normal 
 w140 AZS MA Normal 
 w147 AZS MA Normal 
 w149 AZS SCOS Stroke 
 w152b AZS SCOS Parotiditis 
 w154 AZS SCOS Inguinal Hernia (6yo, 7yo) 
 w160 AZS HP Normal 
 w162 AZS SCOS Normal 
 w165 AZS HP Normal 
 w166 AZS HP Epilepsy 
 w175 AZS MA Normal 
 w176 AZS SCOS Normal 
 w183 AZS HP Left scrotal hydrocele 
 w186 AZS SCOS Normal 
 w187 AZS MA Normal 
 w195 AZS SCOS Left varicocele, Orchitis (24yo) 
 w220 AZS SCOS Normal 
 w227 AZS HP Hepatitis C, ex-alcoholic 
Control 
(n=7) w58 ANEJACUL HP Paraplegy  
 w90 ANEJACUL HP Diabetes Mellitus 
 w103 ANEJACUL HP Psycologic anejaculation 
 w106 ANEJACUL SCOS Paraplegy  
 w116 ANEJACUL HP Paraplegy 
 w128 OLIGO-ASTHE HP Normal 
 w164 OLIGO-ASTHE HP Normal 
ANEJACUL – anejaculation; AZS –azoospermia; HP- hypospermatogenesis; MA –maturation arrest; 
OLIGO-ASTHE – oligo-asthenozoospermia SCOS – Sertoli-Cell-Only Syndrome; Shaded samples had 
no expression for at least one of the studied genes.   
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Table 3 – AKAP4 and STAG3 expression results  
Gene Type Rxn 
Effic. 
Expression Std. Error 95% C.I. P(H1) Result 
18S REF 0.9558 1.000         
AKAP4 TRG 0.9346 0.011 0.000 - 0.645 0.0-62.299 0.007 DOWN 
STAG3 TRG 0.9829 0.050 0.001 - 2.076 0.0-114.426 0.038 DOWN 
REF – Reference. TRG – Target. Rxn Effic. – Reaction efficiency. Std. Error – Standard 
Error. 95% C.I. – 95% confidence interval. P(H1) - Probability of alternative hypothesis 
that difference between sample and control groups is due only to chance. 
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